ArticleLeukemia research reports2026

CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Masuho Saburi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.